Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Br J Clin Pharmacol ; 89(7): 2254-2262, 2023 07.
Article in English | MEDLINE | ID: mdl-36811146

ABSTRACT

AIMS: This study aimed to characterize the population pharmacokinetic parameters of intravenously administered amikacin in newborns and assess the effect of sepsis in amikacin exposure. METHODS: Newborns aged ≥3 days who received at least 1 dose of amikacin during their hospitalization period were eligible for the study. Amikacin was administered intravenously during a 60-min infusion period. Three venous blood samples were taken from each patient during the first 48 h. Population pharmacokinetic parameter estimates were obtained using a population approach with the programme NONMEM. RESULTS: Data from 329 drug assay samples were obtained from 116 newborn patients (postmenstrual age [PMA] 38.3, range 32-42.4 weeks; weight 2.8, range 1.6-3.8 kg). Measured amikacin concentrations ranged from 0.8 to 56.4 mg/L. A 2-compartment model with linear elimination produced a good fit of the data. Estimated parameters for a typical subject (2.8 kg, 38.3 weeks) were clearance (Cl = 0.16 L/h), intercompartmental clearance (Q = 0.15 L/h), volume of distribution of the central compartment (Vc = 0.98 L) and peripheral volume of distribution (Vp = 1.23 L). Total bodyweight, PMA and the presence of sepsis positively influenced Cl. Plasma creatinine concentration and circulatory instability (shock) negatively influenced Cl. CONCLUSION: Our main results confirm previous findings showing that weight, PMA and renal function are relevant factors influencing newborn amikacin pharmacokinetics. In addition, current results showed that pathophysiological states of critically ill neonates, such as sepsis and shock, were associated with opposite effects in amikacin clearance and should be considered in dose adjustments.


Subject(s)
Neonatal Sepsis , Sepsis , Humans , Infant, Newborn , Amikacin/pharmacokinetics , Anti-Bacterial Agents , Neonatal Sepsis/drug therapy , Sepsis/drug therapy , Metabolic Clearance Rate
2.
Zootaxa ; 4845(1): zootaxa.4845.1.8, 2020 Sep 01.
Article in English | MEDLINE | ID: mdl-33056789

ABSTRACT

Psectrascelis is one of the most specious genus of darkling beetles of South America, comprising 82 species that inhabit arid and semiarid environments. The species are distributed mainly in Argentina and Chile. In general, the taxonomy of several species in this group has been difficult to approach. An example is Psectrascelis pilosa Solier and Psectrascelis conjugens Fairmaire, species morphologically similar which presents a rather poor original description and mislabelled. These species are distributed sympatrically in coastal terraces at the northern side of Huasco river, northern Chile. We collected several specimens of Psectrascelis on the southern side of Huasco river which are morphologically similar to P. pilosa. Morphological and genetic analysis support the description of the species Psectrascelis ammophila sp. nov., which is more closely related to Psectrascelis elongata and Psectrascelis pilipes specularis than other morphologically similar species (Psectrascelis pilosa and Psectrascelis conjugens). The importance of the Huasco river as barrier and the evolutionary convergence is discussed to explain the crypsis and the phylogenetic pattern found.


Subject(s)
Coleoptera , Animals , Bees , Biological Evolution , Chile , Phylogeny
SELECTION OF CITATIONS
SEARCH DETAIL